Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests
Complete the form below to unlock access to ALL audio articles.
The permit will enable patients and physicians residing in the State of New York to gain access to the Company's miRview® mets, miRview® squamous, and miRview® meso tests. The Company is now working to gain NYS DOH approval for the first of its second generation tests -- miRview® mets2.
"We are pleased that these microRNA-based diagnostic products are now available to residents of all 50 U.S. states including New York State. Receipt of this permit confirms that Rosetta's CAP-accredited, CLIA-certified laboratory meets the strict requirements of New York State for quality-controlled, accurate and reliable clinical laboratory services," noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. "Rosetta Genomics has made considerable investment in the development of our proprietary microRNA technology platform, and today we have a robust portfolio of diagnostic tests on the market, nearing commercial launch and in development. We look forward to providing the benefits of these powerful diagnostic products to a growing number of clinicians and patients."
